Oxaliplatin plus gemcitabine as a salvage schedule for hormone-refractory prostate adenocarcinoma.
Clin Transl Oncol
; 10(6): 372-4, 2008 Jun.
Article
en En
| MEDLINE
| ID: mdl-18558585
ABSTRACT
We report a case of hormone-refractory prostate cancer (HRPC) treated with oxaliplatin plus gemcitabine in a third-line schedule after liver progression, with an excellent clinical, biochemical and radiological response and with an acceptable tolerance. Prior chemotherapy regimens included docetaxel plus estramustine and oral etoposide. To our knowledge, this is the first report that shows this approach in an HRPC patient.
Search on Google
Banco de datos:
MEDLINE
Asunto principal:
Neoplasias de la Próstata
/
Adenocarcinoma
/
Protocolos de Quimioterapia Combinada Antineoplásica
/
Terapia Recuperativa
Límite:
Humans
/
Male
/
Middle aged
Idioma:
En
Año:
2008
Tipo del documento:
Article